The Effects of Propranolol on Fear of Tooth or Molar Extraction

April 16, 2020 updated by: Prof. dr. J. de Lange, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Effects of Propranolol on Fear of Dental Extraction: Study Protocol for a Randomized Placebo-controlled Trial.

Randomized, placebo-controlled, double-blind, parallel group clinical trial evaluating the anxiolytic effects of propranolol on fear of wisdom tooth removal. It is hypothesized that, compared to placebo, perioperative oral propranolol reduces dental trait anxiety at 1 month follow-up after wisdom tooth removal.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

RATIONALE Tooth and molar removals are among the most feared interventions in dentistry and oral and maxillofacial surgery (OMFS). Anxiety for these procedures not only produces discomfort to the patient, but may also induce patient behavior that impedes surgery, thereby increasing operative time and complicating postoperative recovery. In addition, it has been found that having undergone an extraction poses a significantly increased risk for developing chronic apprehension for dental surgical procedures, disproportionate forms of dental anxiety (i.e., dental phobia), and symptoms of post-traumatic stress. Addressing these problems effectively requires an intervention that reduces both state anxiety during surgery and dental trait anxiety in the long term.

OBJECTIVE The purpose of this trial is to determine the anxiolytic effects of the ß-adrenoreceptor antagonist propranolol on patients with high levels of fear in anticipation of dental extraction.

METHODS Trial design: Randomized, placebo-controlled, two-group, parallel, double-blind, single center trial of 34 participants. Population and recruitment: Consecutive patients, referred by their dentist to the department of Oral and Maxillofacial Surgery of the Academic Medical Center of the University Amsterdam, for at least two tooth and/or molar removals, with self-reported high to extreme fear in anticipation of dental extraction. Intervention: Two 40 mg propranolol capsules one hour prior to dental extraction, followed by one 40 mg capsule directly postoperatively. Comparator: Placebo capsules. Primary outcome: Dental trait anxiety score reduction from baseline to 4-weeks follow-up. Secondary outcomes: Self-reported anxiety during surgery; physiological parameters (heart rate and blood pressure) during recall of the crucial fear-related memory; self-reported vividness and emotional charge of the crucial fear-related memory.

RISKS AND BENEFITS ASSOCIATED WITH PARTICIPATION Participants of the trial will undergo regular dental extraction procedures (treatment as usual), with an additional potentially anxiolytic pharmacological intervention (propranolol) or placebo. The most important known side-effects of propranolol are mild and self-limiting.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amsterdam, Netherlands, 1105 AZ
        • Dept. of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  1. Signed written informed consent
  2. ≥ 18 Years of age on entry to the study
  3. Self-reported high to extreme fear of tooth or molar removal
  4. Dutch or English-speaking

Exclusion criteria

  1. Asthma or other obstructive pulmonary disease
  2. Cardiac failure
  3. Cardiac arrhythmia
  4. Renal failure
  5. Insulin-dependent diabetes mellitus
  6. Pregnant or breast-feeding
  7. Current use of another ß-adrenoreceptor antagonist
  8. Current use of anxiolytic or antidepressant medication
  9. Currently in psychotherapy for dental anxiety
  10. Systolic blood pressure < 100 mmHg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Propranolol
capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
Oral propranolol capsules
Other Names:
  • propranolol hydrochloride
  • propranolol HCl
Placebo Comparator: Placebo
capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
Oral propranolol capsules
Other Names:
  • propranolol hydrochloride
  • propranolol HCl

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline at 1 month follow-up in Short version of the Dental Anxiety Inventory (S-DAI)
Time Frame: Change from baseline at 1 month follow-up
dental trait anxiety
Change from baseline at 1 month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline at 1 month follow-up in Self-reported vividness and emotional charge of the crucial fear-related memory
Time Frame: Change from Baseline at 1 month follow-up
Visual analogue scale
Change from Baseline at 1 month follow-up
Change from baseline at 1 month follow-up in State anxiety during treatment
Time Frame: Change from Baseline at 1 month follow-up
Visual analogue scale
Change from Baseline at 1 month follow-up
Change from baseline at 1 month follow-up in Physiological parameters (heart rate and blood pressure) during recall of the crucial fear-related memory
Time Frame: Change from Baseline at 1 month follow-up
Change from Baseline at 1 month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: prof. dr. J. de Lange, MD, DDS, PhD, Academic Medical Center (AMC) of Amsterdam
  • Study Director: prof. dr. A. de Jongh, DDS, PhD, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2014

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

October 7, 2014

First Submitted That Met QC Criteria

October 17, 2014

First Posted (Estimate)

October 20, 2014

Study Record Updates

Last Update Posted (Actual)

April 17, 2020

Last Update Submitted That Met QC Criteria

April 16, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dental Anxiety

Clinical Trials on Propranolol

3
Subscribe